Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New registry aims to sharpen liver tumor ablation techniques

NCT ID NCT04107766

Knowledge-focused Sponsor: Ethicon, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tracked over 1,200 people with liver cancer who received microwave ablation, a procedure that uses heat to destroy tumors. Researchers collected data over 5 years to see how well the ablation worked and how long patients lived. The goal was to create better guidelines for using this technique in the future.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Microwave ablation (device procedure)
What this could lead to
If successful, this registry could provide doctors with better guidelines for using microwave ablation to treat liver tumors, potentially improving outcomes.
What could go wrong
This was an observational study, not a controlled trial, so it cannot prove that the ablation technique itself improves survival. The study was also terminated early, which may limit the data collected.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

1,254 people

The number who actually took part.

Started

Jan 2020

Finished

Jun 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with at least one soft-tissue liver lesion ablated with the NEUWAVE Microwave Ablation System or NEUWAVE Microwave Ablation System with Ablation Confirmation.

Ages

22 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Patients who underwent or are scheduled to undergo a microwave ablation of one or more liver lesions with the NEUWAVE Microwave Ablation System per the device's Instructions for Use (IFU). 2. Patients with signed informed consent (or waiver approved by IRB/EC) who are willing to comply with the assessment schedule, and willing to have data included in the database. 3. Patients greater than or equal to 22 years old at the time of informed consent (or waiver approved by IRB/EC). Exclusion Criteria: 1. Patients with a life expectancy of less than 1 year, in the opinion of the treating physician. 2. Use of microwave ablation purely as a transection tool, rather than focused liver lesion ablation. 3. Patient is currently participating, or planning to participate, in another NeuWave/Ethicon-funded clinical trial or registry studying microwave ablation in the liver. Note: roll-over patients from previous NeuWave trials are permitted.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cancer of the liver are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

carcinoma of liver and intrahepatic biliary tract liver and intrahepatic bile duct neoplasm liver cancer Liver Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cancer of the liver Liver cancer Neoplasms, liver

Contacts and locations

Locations

  • Cedars Sinai Medical Center

    Los Angeles, California, 90048, United States

  • David Geffen School of Medicine at UCLA

    Los Angeles, California, 90095, United States

  • Hôpital Européen Georges-Pompidou

    Paris, 75015, France

  • ICAHN School of Medicine at Mount Sinai

    New York, New York, 10029, United States

  • Loma Linda University Medical Center

    Loma Linda, California, 92354, United States

  • MD Anderson Cancer Center

    Houston, Texas, 77030, United States

  • Mayo Clinic

    Jacksonville, Florida, 32224, United States

  • Memorial Sloan Kettering Cancer Center

    New York, New York, 10065, United States

  • Norfolk and Norwich University Hospital

    Norwich, NR4 7UY, United Kingdom

  • Olive View UCLA

    Sylmar, California, 91342, United States

  • Radboud UMC

    Nijmegen, 6525 GA, Netherlands

  • Renji Hospital, Shanghai Jiao Tong University School of Medicine

    Shanghai, 200120, China

  • Sarasota Memorial Hospital

    Sarasota, Florida, 34239, United States

  • Seoul National University Bundang Hospital (SNUBH)

    Seongnam-si, Gyeonggi-do 13620, South Korea

  • Singapore General Hospital

    Singapore, 168582, Singapore

  • St. James's University Hospital

    Leeds, LS9 7TF, United Kingdom

  • Sutter Institute for Medical Research

    Sacramento, California, 95816, United States

  • Tan Tock Seng Hospital

    Singapore, 308433, Singapore

  • Tenon Hospital

    Paris, 75020, France

  • The First Affiliated Hospital, Sun Yat-sen University

    Guangzhou, Guangdong, 510000, China

  • The Royal Marsden Hospital

    London, SW3 6JJ, United Kingdom

  • Thomas Jefferson University

    Philadelphia, Pennsylvania, 19107, United States

  • University Hospital Regensburg

    Regensburg, 93053, Germany

  • University Medical Center Goningen

    Groningen, 9713 GZ, Netherlands

  • University of Virginia

    Charlottesville, Virginia, 22908, United States

  • University of Washington Medical Center

    Seattle, Washington, 98101, United States

  • University of Wisconsin At Madison

    Madison, Wisconsin, 53792, United States

  • VUMC Amsterdam

    Amsterdam, 1081 HV, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.